JP2005504789A - 癌治療のための２−アロイルイミダゾール化合物 - Google Patents

癌治療のための２−アロイルイミダゾール化合物 Download PDF

Info

Publication number
JP2005504789A
JP2005504789A JP2003526403A JP2003526403A JP2005504789A JP 2005504789 A JP2005504789 A JP 2005504789A JP 2003526403 A JP2003526403 A JP 2003526403A JP 2003526403 A JP2003526403 A JP 2003526403A JP 2005504789 A JP2005504789 A JP 2005504789A
Authority
JP
Japan
Prior art keywords
substituted
alkyl
group
unsubstituted
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003526403A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005504789A5 (enExample
Inventor
圭三 古屋
スン，リーチュン
光則 小野
ジェームス，デービッド
イン，ウィーウェン
チェン，ショウチュン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synta Phamaceuticals Corp
Original Assignee
Synta Phamaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synta Phamaceuticals Corp filed Critical Synta Phamaceuticals Corp
Publication of JP2005504789A publication Critical patent/JP2005504789A/ja
Publication of JP2005504789A5 publication Critical patent/JP2005504789A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2003526403A 2001-09-13 2002-08-28 癌治療のための２−アロイルイミダゾール化合物 Pending JP2005504789A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32210501P 2001-09-13 2001-09-13
PCT/US2002/027514 WO2003022274A2 (en) 2001-09-13 2002-08-28 2-aroylimidazole compounds for treating cancer

Publications (2)

Publication Number Publication Date
JP2005504789A true JP2005504789A (ja) 2005-02-17
JP2005504789A5 JP2005504789A5 (enExample) 2006-01-05

Family

ID=23253436

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003526403A Pending JP2005504789A (ja) 2001-09-13 2002-08-28 癌治療のための２−アロイルイミダゾール化合物

Country Status (6)

Country Link
US (2) US6743919B2 (enExample)
EP (1) EP1427413A2 (enExample)
JP (1) JP2005504789A (enExample)
AU (1) AU2002323475B2 (enExample)
CA (1) CA2460345A1 (enExample)
WO (1) WO2003022274A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005035977A (ja) * 2003-07-16 2005-02-10 Buddhist Tzu Chi General Hospital 新規なγ−ブチロラクトン化合物及びその医薬組成物
JP2009517401A (ja) * 2005-11-23 2009-04-30 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 腫瘍形成性ｒａｓ特異的細胞障害性化合物およびその使用法
JP2011527342A (ja) * 2008-07-07 2011-10-27 エックスカバリー ホールディング カンパニー エルエルシー Ｐｉ３ｋアイソフォーム選択的阻害剤

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002323475B2 (en) * 2001-09-13 2006-09-28 Synta Pharmaceuticals Corp 2-aroylimidazole compounds for treating cancer
MXPA04007767A (es) * 2002-02-12 2004-10-15 Wisconsin Alumni Res Found Sintesis de compuestos indol tiazol como ligandos para receptor de ha.
EP1697352B1 (en) 2003-09-24 2012-06-27 Vertex Pharmceuticals Incorporated 4-azole substituted imidazole compositions useful as inhibitors or c-met receptor tyrosine kinase
CA2544335A1 (en) * 2003-10-31 2005-05-12 Auckland Uniservices Limited Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents
GB0403781D0 (en) * 2004-02-20 2004-03-24 Astrazeneca Ab Chemical compounds
WO2006034440A2 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
CA2580857A1 (en) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
CA2580844A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase
CN101083982A (zh) 2004-09-20 2007-12-05 泽农医药公司 用于治疗硬脂酰CoA去饱和酶介导的疾病的杂环衍生物
US7829712B2 (en) 2004-09-20 2010-11-09 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
AU2005286846A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
TW200624427A (en) 2004-09-20 2006-07-16 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
WO2006128129A2 (en) * 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
US8541457B2 (en) 2005-06-03 2013-09-24 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
JP2009509128A (ja) * 2005-08-09 2009-03-05 テトラロジック ファーマシューティカルズ コーポレーション 増殖性疾患の治療
EP1998766A2 (en) * 2005-12-16 2008-12-10 Ironwood Pharmaceuticals, Inc. Useful indole compounds
US7649098B2 (en) * 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
WO2008005908A2 (en) 2006-07-07 2008-01-10 Forest Laboratories Holdings Limited Pyridoimidazole derivatives
WO2008085302A1 (en) * 2006-12-20 2008-07-17 Merck & Co., Inc. Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
TW200920355A (en) * 2007-09-06 2009-05-16 Lexicon Pharmaceuticals Inc Compositions and methods for treating immunological and inflammatory diseases and disorders
ES2537624T3 (es) * 2007-10-26 2015-06-10 F. Hoffmann-La Roche Ag Derivados purina útiles como inhibidores de la quinasa PI3
BRPI0909614A2 (pt) 2008-05-30 2015-09-22 Hoffmann La Roche "composto, composição farmacêutica, método de tratamento de um transtorno hiperproliferativo em um mamífero, processo para a preparação de uma composição farmacêutica, método para a inibição ou modulação da atividade de quinase de lipídio em um mamífero, kit para o tratamento de condição mediada por pi3k e método de preparação de um composto da fórmula
BRPI1009022A2 (pt) 2009-05-27 2016-03-08 Hoffmann La Roche "composto, composição farmacêutica, processo para produzir uma composição farmacêutica, uso de um composto, método para tratamento de uma doença ou transtorno e kit"
US9205086B2 (en) 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
KR101531117B1 (ko) 2010-07-14 2015-06-23 에프. 호프만-라 로슈 아게 Pi3k p110 델타에 대해 선택적인 퓨린 화합물, 및 사용 방법
EP2606031B1 (en) 2010-08-20 2017-09-27 Amira Pharmaceuticals, Inc. Autotaxin inhibitors and uses thereof
RS53768B1 (sr) 2010-12-16 2015-06-30 F. Hoffmann-La Roche Ag. Triciklična pi3k inhibitorna jedinjenja i postupci korišćenja
WO2012166415A1 (en) * 2011-05-27 2012-12-06 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
JP2014532712A (ja) 2011-11-02 2014-12-08 シンタ ファーマシューティカルズ コーポレーション トポイソメラーゼｉ阻害剤とｈｓｐ９０阻害剤の組合せを使用する癌療法
AU2012332424A1 (en) 2011-11-02 2014-06-05 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with platinum-containing agents
AU2012339679A1 (en) 2011-11-14 2014-06-12 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with BRAF inhibitors
CN108841778B (zh) * 2018-04-28 2022-05-17 大连普瑞康生物技术有限公司 一种红豆杉细胞组织培养物
EP4192828A1 (en) 2020-08-04 2023-06-14 Nura Bio, Inc. Substituted pyridine derivatives as sarm1 inhibitors
WO2022060812A1 (en) 2020-09-16 2022-03-24 Nura Bio, Inc. Substituted pyridine derivatives as sarm1 inhibitors
KR20240041987A (ko) 2021-07-28 2024-04-01 누라 바이오, 인크. Sarm1 억제제로서 치환된 피리딘 유도체
US20240417399A1 (en) * 2021-10-14 2024-12-19 Galileo Biosystems, Inc. Aryl hydrocarbon receptor (ahr) modulators and therapeutic uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0272810A3 (en) * 1986-11-26 1988-07-20 Harbor Branch Oceanographic Institution, Inc. Antitumor and antiviral alkaloids
US4866084A (en) * 1987-07-17 1989-09-12 Harbor Branch Oceanographic Institution, Inc. Topsentin compounds effective against viruses and certain tumors
US5290777A (en) * 1993-02-24 1994-03-01 Regents Of The Univ. Of California Use for topsentin compounds and pharmaceutical compositions containing same
EP0862553A4 (en) * 1995-10-03 1999-02-03 Scripps Research Inst CBI ANALOG OF CC-1065 AND THE DUOCARMYCINES
EP0935463B1 (en) 1996-10-31 2004-01-21 Harbor Branch Oceanographic Institution, Inc. Use of anti-neurogenic inflammatory compounds and compositions
WO1999042092A2 (en) 1998-02-20 1999-08-26 Harbor Branch Oceanographic Institution, Inc. Compounds and methods of use for treatment of neurogenic inflammation
WO2000002857A1 (en) 1998-07-08 2000-01-20 Harbor Branch Oceanographic Institution, Inc. Bis-indole derivatives and their use as antiinflammatory agents
CN1310906C (zh) * 1999-05-21 2007-04-18 肖斯公司 用作p38激酶抑制剂的吲哚类型的衍生物
AU2002323475B2 (en) * 2001-09-13 2006-09-28 Synta Pharmaceuticals Corp 2-aroylimidazole compounds for treating cancer

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005035977A (ja) * 2003-07-16 2005-02-10 Buddhist Tzu Chi General Hospital 新規なγ−ブチロラクトン化合物及びその医薬組成物
JP2009517401A (ja) * 2005-11-23 2009-04-30 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 腫瘍形成性ｒａｓ特異的細胞障害性化合物およびその使用法
JP2011527342A (ja) * 2008-07-07 2011-10-27 エックスカバリー ホールディング カンパニー エルエルシー Ｐｉ３ｋアイソフォーム選択的阻害剤

Also Published As

Publication number Publication date
WO2003022274A3 (en) 2003-07-10
US6743919B2 (en) 2004-06-01
AU2002323475B2 (en) 2006-09-28
US20030096836A1 (en) 2003-05-22
US7081466B2 (en) 2006-07-25
WO2003022274A2 (en) 2003-03-20
US20040186129A1 (en) 2004-09-23
EP1427413A2 (en) 2004-06-16
CA2460345A1 (en) 2003-03-20

Similar Documents

Publication Publication Date Title
JP2005504789A (ja) 癌治療のための２−アロイルイミダゾール化合物
AU2002323475A1 (en) 2-aroylimidazole compounds for treating cancer
JP5210867B2 (ja) 置換ベンゾイミダゾールおよびその製造方法
JP5938400B2 (ja) ピロリル置換ジヒドロインドール−２−オン誘導体、調製方法及びそれらの用途
CN103124730A (zh) 杂环炔苯类化合物及其药用组合物和应用
JP2022532718A (ja) Ａｃｓｓ２阻害剤およびその使用方法
US6958348B2 (en) 3-glyoxylamideindoles for treating cancer
AU2002323474A1 (en) 3-glyoxlylamideindoles for treating cancer
EP1432709B1 (en) 1-glyoxlylamide indolizines for treating cancer
JP2023085367A (ja) Ｉｄｏ／ｔｄｏ阻害剤
JP4599164B2 (ja) ３位が複素環式基によって置換されたピリドインドロン誘導体、それらの製造法およびそれらの治療用途
KR102532912B1 (ko) 자궁 내막증 치료용 인돌의 신규 유도체
TW202332441A (zh) 作為malt-1抑制劑之經取代雙環雜環
JP2024009788A (ja) Ｉｄｏ／ｔｄｏ阻害剤
CN118946559A (zh) 大环化合物及其作为激酶抑制剂的用途
HK1079507A (en) 1-glyoxylamide indolizines for treating cancer
HK1063322B (en) 1-glyoxylamide indolizines for treating cancer
EP1598352A1 (en) 1-Glyoxylamide indolizines for treating cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050825

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090609

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091106